Genmab

	15/6 10:28 af Sukkeralf	yes nice article for NICE
	15/6 10:10 af Bulder	Yes, the point is that the OS data will help convincing the more conservative councils like the Danish and English.
	15/6 10:08 af E L	Nice article!
	15/6 09:50 af Bulder	Maia OS data. Det er stort - siger Plesner (link)
	15/6 09:31 af E L	the Genmab Investor Presentation is updated for- June 2021, so maybe they'll use that. Not much change, except for amivantamab approval and the epco data update on p 11 (link)
	15/6 09:14 af E L	Citi Healthcare conference 15-16 June, but I don't think there is a webcast, is there?
	15/6 08:39 af Doublo	Tak Bullish
	15/6 08:25 af Helge Larsen/PI-redaktør	Aktier/tendens: Aktiemarkederne i grønt forud for rentemøde (link)
	15/6 07:13 af Helge Larsen/PI-redaktør	Tirsdagens danske avisuddrag med FED, Flying Tiger og Solselskaber (link) med-fed-flying-tiger-og-solselskaber
	15/6 07:03 af Helge Larsen/PI-redaktør	Asien: Japanske aktier trækker fra efter plusser i USA (link)
	15/6 07:03 af Helge Larsen/PI-redaktør	God morgen. :-)
	14/6 18:56 af Solsen	CD20xCD3+CD37 er måske Genmabs trumf over Roche.
	14/6 18:54 af Solsen	Jeg tror Genmab/Abbvies CD37 kan overraske stort :-)
	14/6 18:32 af Legolas23	Jo
	14/6 18:27 af Sukkeralf	(link)
	14/6 18:27 af Sukkeralf	Lidt CD37 ADC data - det target skal vi vel så småt begynde at forholde os til
	14/6 17:55 af Bulder	Er det ikke 44,83?
	14/6 17:35 af Legolas23	US add-varianten er tæt på ATH...
	14/6 17:24 af E L	I have a feeling total Dara sales estimates are going up. Q1 forecast was conservative and comments have led to believe they will be adjusted upward. Even though our share of the pie (the royalties) MAY become a bit smaller due to arbitrage, the size of the pie (total sales) is getting bigger. which compensates a lot.
	14/6 17:08 af Solsen	Det er en super udvikling på baggrund af en stadig uafklaret patent- og royaltysag.
	14/6 17:06 af Bulder	Sølle 35 kr til rekorden.
	14/6 17:05 af Bulder	Jeg tror denne optur er kommet bag på de fleste. Havde først forventet noget lignende i forbindelse med nyheder i H2.
	14/6 17:00 af Helge Larsen/PI-redaktør	Luk i HOD. :-)
	14/6 16:58 af Bulder	Exactly. Will open the eyes on more conservative MD's, who look at OS more than PFS. But Søren is right that it will not mean anything on the shareprice short term.

	14/6 16:53 af E L	I have to disagree with Søren there btw, I actually do think it is very important data, cementing Dara in SOC. I know we have gotten so used to good data for Dara we don't really consider anything important anymore, but it really is ; MD's make their decisions on data like this
	14/6 16:34 af royal	@ pensionisten Du kunne jo ikke se st jeg havde hævet venstre arm da jeg skrev, hvilket betyder at der er tale om ironi. :-)
	14/6 16:34 af Hen	2738.
	14/6 16:26 af Bulder	Med en fornuftig lukkeauktion, skulle vi vel kunne passere 2700. Og så er der ikke langt op til lukkerekorden.
	14/6 16:15 af gdn55	Det vil vise sig.
	14/6 16:13 af Bulder	Ja, Ritzau er rigtig oppe på beatet, her 14 dage efter nyheden kom ud.
	14/6 16:11 af Helge Larsen/PI-redaktør	Genmab: Janssen fremlægger yderligere data for Darzalex (link)
	14/6 15:39 af Raun	Nej
	14/6 14:39 af Raun	Tror du får ret med 27xx..... Grunden til den store omsætning, tror jeg er grundet en del gevinsthjemtagning.... Når først US åbner, så kan gevinsthjemtagning ikke holde den tolbage længere ;-)
	14/6 14:31 af royal	Der er vild megen omsætning idag. Luk i 27xx :-)
	14/6 12:53 af Raun	;-)
	14/6 12:48 af Solsen	33 point i dag er vel også en slags modstand ;-)
	14/6 12:47 af Raun	Det kunne det i hvert fald godt ligne :-)
	14/6 12:45 af Rondo	var det omkring 2690 Genmab ville kunne mærke modstand... ?
	14/6 12:27 af E L	bit similar to BMS's HuMax-IL8, also below the radar, but recently a small new PhII in head and neck squamous cell carcinoma was started (link)
	14/6 12:25 af E L	lol. but you'll have plenty of time to refresh your memory before they will publish some results i imagine.
	14/6 11:59 af JørgenVarnæs	Funny with this Lundbeck stuff - its been going on for so long, I’ve forgotten everything about it…
	14/6 11:06 af E L	yes, agree, definitely positive
	14/6 10:53 af JørgenVarnæs	Exciting stuff EL. Primary completion is also imminent
	14/6 10:50 af gentogen	Thanks E L!! Great that we can count on you to watch out for everything. With very few updates on CT this looks as positive news.
	14/6 10:42 af E L	with a therapeutic effect on disease burden and function. The ability to offer a treatment that will change the course of the disease will offer a fundamental improvement compared to currently available symptomatic treatments. Orphan drug designation was granted by EMA in April 2021. The purpose of this study is to investigate the safety of a single dose of Lu AF82422, how well it is tolerated and what the body does to the drug in healthy subjects and patients with Parkinson’s diseaseNCT03611569
	14/6 10:42 af E L	Lu AF82422 is a monoclonal antibody (mAb) targeting the pathological form of the protein alpha-synuclein that is believed to play a pivotal role in the development and progression of e.g. multiple system atrophy (MSA) and Parkinson’s disease and other neurodegenerative disorders. By targeting pathological alpha-synuclein with an antibody that will inhibit aggregation and potentially clear pathological alpha-synuclein from the brain, the project aims to demonstrate delay of disease progression -
	14/6 10:41 af E L	Lundbeck watchers did not do their job, as it was also in the Q1 report ;-) (link)
	14/6 10:39 af E L	EMA Committee for Orphan Medicinal Products in April awarded Lu AF82422 Orphan drug designation (link) 2.1.4
	14/6 09:26 af Stroka	De gode takter forsætter. :-)
	14/6 08:34 af Stroka	God morgen. :-)